Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Positive concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer time period between blood and tissue sampling and was higher in colorectal cancer than in other malignancies.
|
31199507 |
2020 |
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC.
|
30720004 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer.
|
31782995 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<b>Results & conclusion:</b> The genotype CT of rs8720 was significantly increased risk of CRC, decreased overall survival and event-free survival, and KRAS mRNA and protein expressions were significantly increased in individuals with rs8720 CT, TT genotype. rs8720 may be an important factor in CRC development and prognosis.
|
31729889 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The G12D KRAS mutation and CR-1 abnormalities are significantly associated as two signature biomarkers with potential clinical characteristics for the detection of CRC development.
|
31692030 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Collectively, our study highlights the importance of REG4 in promoting CSCs properties induced by KRAS mutation, and provides a new therapeutic strategy for CRC harboring both APC and KRAS mutations.
|
31605540 |
2020 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS-mutated HCT116 colorectal cancer (CRC) cells.
|
31396956 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The KRAS mutation is common in colorectal cancer, however the correlation between KRAS status and micrometastases has not been thoroughly clarified.
|
31720935 |
2020 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we will present up to date information on the role of miRNA-31-3p and miR-31-5p in CRC with a particular focus in treatment response of metastatic K-RAS wild-type CRC treated with anti-EGFR molecules.
|
31786833 |
2020 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
|
30737098 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
LY3214996 also exhibited synergistic combination benefit with a pan-RAF inhibitor in a KRAS-mutant colorectal cancer xenograft model.
|
31744895 |
2020 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The strategies to target energy metabolism for the metabolic alterations in mutated KRAS CRC are also introduced.
|
30341899 |
2019 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
m-KRAS is associated with worse OS in patients presenting with colorectal cancer and liver metastases undergoing resection of the primary tumor and metastatic disease.
|
30276588 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.
|
30896620 |
2019 |
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To better understand the cellular reprogramming which occurs in mutant KRAS cells, we have undertaken a systems-level analysis of four CRC cell lines which express either wild type (wt) KRAS or the oncogenic KRAS<sup>G13D</sup> allele (mtKRAS).
|
31133691 |
2019 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
|
31409052 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
|
31222012 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
|
30661213 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.
|
30613980 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Between October 2007 and May 2016, 328 patients underwent surgery for CRCs that were analyzed for KRAS mutations at a referral university hospital.
|
28277374 |
2019 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
|
31057298 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
|
31771279 |
2019 |
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The proportion of HER2 amplifications in KRAS-positive CRC patients was 4.4%, which was lower than that in KRAS -negative CRC patients (14.3%).
|
31729406 |
2019 |
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |